ANN ARBOR, MI -- (Marketwired) -- 03/05/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the fourth quarter and full year ended December 31, 2014.
"The past year has been the most impactful yet for ETC-1002 and Esperion," said Tim M. Mayleben, president and chief executive officer of Esperion. "Positive top-line results from the ETC-1002-008 study positioned us to complete a successful follow-on offering; the LDL-cholesterol lowering hypothesis was reaffirmed by the scientific community; and the PPAR partial clinical hold was removed by the FDA. We look forward to building on this momentum in the months ahead as we complete the ETC-1002 Phase 2b clinical program this month, hold a mid-year End-of-Phase 2 meeting with the FDA, and advance ETC-1002 into Phase 3 before year end."
Help employers find you! Check out all the jobs and post your resume.
"The past year has been the most impactful yet for ETC-1002 and Esperion," said Tim M. Mayleben, president and chief executive officer of Esperion. "Positive top-line results from the ETC-1002-008 study positioned us to complete a successful follow-on offering; the LDL-cholesterol lowering hypothesis was reaffirmed by the scientific community; and the PPAR partial clinical hold was removed by the FDA. We look forward to building on this momentum in the months ahead as we complete the ETC-1002 Phase 2b clinical program this month, hold a mid-year End-of-Phase 2 meeting with the FDA, and advance ETC-1002 into Phase 3 before year end."
Help employers find you! Check out all the jobs and post your resume.
